Search This Blog

Tuesday, June 17, 2025

Top FDA Official Admits She Refused the Covid-19 Vaccine While Pregnant

 One of the most powerful figures at the US Food and Drug Administration (FDA) has admitted she refused the Covid-19 mRNA vaccine while pregnant—even as her agency promoted it as “safe and effective” for all pregnant women.

Dr Sara Brenner’s explosive disclosure, made on 15 May 2025 at the MAHA Institute Round Table in Washington, DC, is as revealing as it is troubling.

A preventive medicine physician, Brenner has worked at the FDA since 2019. As the FDA’s Principal Deputy Commissioner—and briefly its Acting Commissioner—Brenner was at the centre of decision-making.

Dr Sara Brenner with Leland Lehrman on 15 May 2025 at the MAHA Institute Round Table in Washington, DC

Prior to that, she was Chief Medical Officer for diagnostics and was detailed to the White House to support the Biden administration’s Covid-19 response. She didn’t just participate in the pandemic response, she helped shape it from within.

“Knowing what I knew—not only about nanotechnology, about medicine, about the medical countermeasures—but also having a very strong and firm grounding in bioethics…there were many things that were not right,” she told the audience.

That someone with her seniority and access to internal data privately rejected the vaccine, while her agency promoted it to millions of pregnant women, presents a profound ethical dilemma.

Brenner’s Concerns about mRNA Safety 

Brenner explained that her decision was driven by a lack of safety data, particularly around the biodistribution of the vaccine’s lipid nanoparticles (LNPs)—the tiny fat particles used to deliver the mRNA into cells. 

“It was unknown at the time what the biodistribution patterns of those products were…That was my primary concern, and that exposure I was very concerned about,” said Brenner. 

She had reason to be cautious. 

As a nanomedicine expert who built an MD/PhD program in the field, Brenner had spent years researching the “biodistribution, excretion, metabolism and toxicities associated with engineered nanoparticles.” 

“Materials that don’t exist in nature—there’s a lot of unknowns,” said Brenner. 

She warned that unintended toxic effects—especially in vulnerable populations like pregnant women—could not be ignored. 

“Regardless of the medical product or the intervention, there’s always going to be the need to evaluate both the intended outcomes…and the unintended consequences,” she cautioned.

Warnings Ignored

Brenner’s concerns echoed those raised in 2021 by Canadian immunologist Dr Byram Bridle, who first exposed internal documents from Japan’s regulatory agency showing that LNPs didn’t remain at the injection site, but travelled throughout the body and accumulated in organs including the ovaries, liver, spleen, and bone marrow.

At the time, Bridle’s warnings were aggressively dismissed. His reputation took a hit, and he faced institutional censure from the University of Guelph, where he was a professor, for speaking out against vaccine mandates.

Dr Byram Bridle, Canadian immunologist. Photo credit: Kenneth Armstrong

Now, Brenner’s comments confirm that these concerns were not only valid—they were quietly shared at the highest levels of the FDA.

During the event, Brenner also revealed that her worries extended to breastfeeding and potential exposure to her child after birth.

A 2022 study published in JAMA Pediatrics detected vaccine-derived mRNA in the breast milk of vaccinated mothers for at least 48 hours—the very scenario Brenner had feared. 

Yet the FDA made little effort to publicly investigate or address the findings, dismissing them with the vague reassurance that there was “no evidence of harm.”

No Mandate for Brenner?

It’s unclear how Brenner managed to avoid the vaccine mandate that applied to all federal employees at the time. She didn’t say. Perhaps she received a religious or medical exemption—but she left that part out.

What she did reveal was that she had concerns—deep enough not to take the vaccine during her pregnancy. Yet she said nothing publicly, while her agency told millions of other women it was safe. 

For many, that silence is hard to accept, and it has left many asking why she didn’t warn other women about a product with ‘zero’ clinical safety data in pregnancy.

No one but Brenner knows the full story. But the ethical contradiction is hard to ignore.

Silence Inside the Castle

Brenner acknowledged the immense pressure inside the FDA to stick to the official narrative. 

“They don’t let you get very far out of the castle at FDA with your talking points,” she admitted nervously.

She described the period as a “dark night of the soul” for many civil servants, a time when even “very obvious things” took bravery to say. 

She eventually found support through a group called Feds for Medical Freedom—federal workers advocating for informed consent, bodily autonomy, and pushing back against government overreach.

A Culture Change?

Today, under a new administration, Brenner says the culture inside the FDA is shifting. She praised Commissioner Dr Marty Makary and said transparency is finally becoming a priority.

“We’re moving very quickly to make it such that there will be more transparency…so that people can see and evaluate for themselves what the truths are.”

But Brenner’s remarks won’t undo what has already happened—especially to those who were vaccine-injured or whose pregnancies were affected.

What her comments do offer is a rare glimpse into the internal dynamics of a government institution that issued sweeping public assurances while failing to acknowledge its own uncertainty.

“There was no acknowledgement of what was unknown. There were only statements and assertions that were really more like beliefs,” Brenner said of the FDA’s messaging during the pandemic.

That may be her most important admission.

This is more than a story about one woman’s personal decision. It is a story about institutional culture, regulatory failure, and the consequences of silence.

Those who spoke up were punished. Those who stayed silent kept their jobs and reputations. And those who were forced to comply were often left to deal with the collateral damage.

When asked whether she believed she had made the right decision in refusing the Covid-19 vaccine, Brenner replied simply, “I believe so.”

Now that she has spoken, the question remains—who else knew, and said nothing?

Maryanne Demasi, 2023 Brownstone Fellow, is an investigative medical reporter with a PhD in rheumatology, who writes for online media and top tiered medical journals. For over a decade, she produced TV documentaries for the Australian Broadcasting Corporation (ABC) and has worked as a speechwriter and political advisor for the South Australian Science Minister.

https://brownstone.org/articles/top-fda-official-admits-she-refused-the-covid-19-vaccine-while-pregnant/

General Mills to remove artificial colors from all its US cereals and foods



General Mills (NYSE: GIS) today announced plans to remove certified colors from all its U.S. cereals and all foods served in K-12 schools by summer 2026. Additionally, the company will work to remove certified colors from its full U.S. retail portfolio by the end of 2027.

For nearly 160 years, General Mills has been providing families quality, great-tasting products across its beloved portfolio of brands.

This change impacts only a small portion of General Mills’ K-12 school portfolio, as nearly all its school offerings today are made without certified colors. Similarly, 85 percent of General Mills’ full U.S. retail portfolio is currently made without certified colors.

“Across the long arc of our history, General Mills has moved quickly to meet evolving consumer needs, and reformulating our product portfolio to remove certified colors is yet another example,” said Jeff Harmening, chairman and CEO, General Mills. “Today, the vast majority of our foods are made without certified colors and we’re working to ensure that will soon apply to our full portfolio. Knowing the trust families place in us, we are leading the way on removing certified colors in cereals and all our foods served in K-12 schools by next summer. We’re committed to continuing to make food that tastes great and is accessible to all."

For decades, General Mills has proven its reformulation capabilities and delivered products that delight consumers and meet a changing landscape. General Mills is the leading provider of whole grains to Americans with other notable efforts including industry-leading sugar-reduction work across General Mills’ K-12 school portfolio, doubling vitamin D in General Mills’ cereals in 2023 to help close nutritional gaps, and reducing sodium by 20 percent across key product categories since 2019.

Medicare Rules Finally Ease Access to Simpler Home Ventilation Devices for COPD

 Newly released Medicare national coverage determinations are set to reshape the home ventilation landscape for chronic obstructive pulmonary disease (COPD).

The final determination of coverageopens in a new tab or window released June 9 takes the long-awaited step of simplifying access to bilevel positive airway pressure (BiPAP) respiratory assist devices and restricts the more expensive home mechanical ventilators to only those who need the additional ventilatory modes and features they offer.

"There's definitely celebrating going on," said Lisa Wolfe, MD, of Northwestern University in Chicago and a member of the technical expert panel who worked on the recommendations to the Centers for Medicare and Medicaid Servicesopens in a new tab or window (CMS).

"Because of the way the old guidelines were written, it was really easier to get a full noninvasive ventilator than it was to get a bilevel PAP. And because of that, a lot of COPD patients were getting these larger noninvasive ventilators -- and they are so much more expensive," she told MedPage Today.

The new regulations simplify the burden of proof for both types of devices. They don't have oxygen qualifications or require proof that a patient has tried and failed BiPAP, so "they can go straight to a vent if they need a significant amount of oxygen," Wolfe said.

Conversely, a patient qualifies for a BiPAP machine based on a blood gas test that shows high carbon dioxide (partial pressure of carbon dioxide ≥52 mm Hg by arterial blood gas during awake hours breathing the prescribed fraction of inspired oxygen), without the prior requirement of having to prove the patient had failed 2-L flow of oxygen or a formal sleep study to document that sleep apnea isn't the predominant cause of hypercapnia as long as the treating physician can attest to that.

The determination will expand the role of sleep labs in making decisions and titrating people on BiPAP beyond diagnoses of obstructive sleep apnea or central sleep apnea to now include COPD. "But the problem is it will significantly cut down access to respiratory therapy in the home," which has been tied to home mechanical ventilator rentals, Wolfe acknowledged.

"This has been a rather controversial area for a long time," said Nicholas Hill, MD, of Tufts University in Boston and a co-chair with Wolfe on the recommendations to CMS.

"As recently as 2013, [a Cochrane review] said that the evidence wasn't sufficiently clear to justify use more than on an investigational basis," he noted.

Key turning points were the publication of two trials proving benefit. A randomized trialopens in a new tab or window from Germany and Austria among 195 stable GOLD stage IV COPD patients showed that use of a standard BiPAP-type machine substantially boosted survival. One-year mortality was 12% with the noninvasive PAP compared with 33% in the control group, a 76% relative reduction in risk (P=0.0004). The BiPAP group also gained an advantage in multiple measures of blood oxygenation and lung function, as well as health-related quality of life.

"Results for 6-min walk distance did not reach the predefined significance level, but the suggested minimal clinically important increase in 6-min walk distance of 54 m was reached by 45 (44%) patients in the intervention group versus 23 (25%) control patients," the authors wrote.

A subsequent study from the U.K.opens in a new tab or window that randomized 116 COPD patients with persistent hypercapnia after recent resolution of respiratory acidemia to either home oxygen alone or with BiPAP-type home ventilation showed a longer median time to readmission or death (4.3 vs 1.4 months, adjusted HR 0.49, P=0.002) and a 17% absolute lower 12-month risk of readmission or death (63.4% vs 80.4%) with the added BiPAP. The difference was driven by a reduction in hospitalizations without a difference in mortality, "but they allowed crossovers, which generally is going to make it hard to show positive outcomes," Hill acknowledged.

Guidelines have shifted to recommend noninvasive home ventilation, and now the CMS regulations are in line with the science, Hill suggested.

"Both these positive studies used simple BiPAP-type devices, not these more expensive ones. And there really isn't any justification for CMS rules to encourage use of these more expensive ones as a first option," he told MedPage Today.

A big change was the creation of a pathway for hospitalized patients to go home with a BiPAP machine, although there are documentation requirements, Wolfe said. "In order to make that work, when a patient is in the hospital, the physicians will need to get an arterial blood gas, not a venous one, because the venous won't count. It has to be arterial. And they have to document that the patient is using the BiPAP machine and what the full settings of the machine are and that they are benefiting from that machine up to and including the last 24 hours that they're admitted to the hospital."

Patients who need more than 4 L of oxygen or who use their PAP machine more than 8 hours a day will still qualify for the "Cadillac" version, Wolfe added. "But other than that, they've made it so easy to get a standard BiPAP machine that you're not going to get the higher-end machine unless you have those significant problems."

The new national coverage determination goes into effect by September, and while it only covers COPD, not any other respiratory conditions for which patients might need respiratory assist devices, Wolfe noted that this additional national coverage determination is anticipated to be forthcoming.

A more intractable problem is getting patients on and using the devices.

"I don't think there's any question that people who would stand to benefit from this are not getting it," Hill said. Even in his own hospital, COPD patients on general medical services often don't get pulmonary consultations and thus typically are not offered noninvasive home ventilation. And of those who do get it, "many of them don't continue when they leave the hospital and not infrequently that's because they don't want to," he explained.

This older population often has comorbidities and socioeconomic and cognitive challenges that make them not good candidates or lead them to decline, Hill noted. Then, "a lot of people who are prescribed and even get to the point of receiving them at home are not going to use them as prescribed. You know, they end up in the closet."

After the first 6 months, continued coverage requires that the patient be using the device at least 4 hours per a 24-hour period on at least 70% of days and achieve some clinical benefit.

Disclosures

Wolfe disclosed no relevant relationships with industry.

Hill disclosed a research grant to his institution from Telesair.


https://www.medpagetoday.com/spotlight/copd/116105

'State Lawmaker Urges Public Health Workers to Get in 'Good Trouble''

 Tennessee state Rep. Justin Jones (D) called on public health workers to get in "good trouble" during the American Public Health Association's Policy Action Institute

opens in a new tab or window on Tuesday.

"Let us get in some good, creative, prophetic, imaginative trouble right now," Jones said, echoing the late Rep. John Lewis (D-Ga.), a prominent civil rights leader.

Jones is no stranger to trouble. In August 2023, he was temporarily expelled from the Tennessee state legislatureopens in a new tab or window following a protest over gun violence in the state capitol, shortly after a shooting at a private Christian school in Nashvilleopens in a new tab or window. A few months later, Jones filed a lawsuitopens in a new tab or window against Tennessee House Speaker Cameron Sexton (R) and House administrative officials.

Given what Jones described as the current assault on immigrants, LGBTQ+ persons, and the poor, he called on public health workers to be advocates and activists. He urged them to show up at town halls and at ribbon cuttings, at church, and any places their lawmakers might be and make their voices heard.

"What is happening is very extreme," he told MedPage Today in a phone call. "This is precisely the time for public health to get back to its roots, which was community organizing."

He also rejected the advice of former Ohio Gov. John Kasich (R) who advised public health workers to "stay in your lane" when it comes to funding and budgeting issues while engaging with lawmakers.

"You're not here to be budgeteers ... That's just not what you do," he said. "Tell them the stories of what happens [when funding is or isn't directed to a certain issue], and let [legislators] figure out how they can find the money."

Jones countered, "I think it's time for people to show up, to get out of their lane, to recognize that public health is an intersectional field," and includes gun violence, systemic racism and poverty, and environmental justice.

Jones also encouraged public health workers to build relationships with "non-traditional" allies. For his part, as chair of the Agriculture Committee, Jones, who grew up in an urban community, began connecting with farmers in rural districts.

"Now's the time to show up in unfamiliar places," he told his colleagues. "When I walk into some of these farms in Maury County, and they got Fox News on, I say ... 'How can we organize together?'"

With support from the farmers, Jones helped defeat a bill that would have given immunity to pesticide companies even if their products made people sick.

Jones said it was important to find "common ground," which appeared to be a theme of the conference, but only to a point.

"This is not the time to be the 'I-told-you-so' folks," he noted, "to say that we have all the answers and that we are these academic elitists who are going to save the whole nation, but this is the time to go to the places that are hurting the most ... to come in humility but also in solidarity, to say that the forces who are attacking our queer kids in schools right now are the same forces who say that [they] don't want to expand Medicaid."

https://www.medpagetoday.com/publichealthpolicy/publichealth/116125